Skip to content
PeptideAgent

Compounding pharmacies in Arizona

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Arizona State Board of Pharmacy regulates compounding pharmacies in Arizona. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Arizona at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Arizona

No verified compounding pharmacies serving Arizona are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Arizona

The Arizona State Board of Pharmacy regulates compounding through Administrative Code rule R4-23-410 (current good compounding practices) and R4-23-670 (sterile pharmaceutical products), both of which require compliance with applicable federal law, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Arizona has no state bulks list. A pharmacy located outside Arizona may not ship prescription-only drugs into the state without a Board-issued nonresident pharmacy permit under rule R4-23-607 and A.R.S. 32-1931, in addition to a valid permit in its home jurisdiction. The Board maintains a public license verification tool for both resident and nonresident pharmacies. [1] [2] [3] [5]

Compounded GLP-1 access in Arizona

Arizona patients using telehealth GLP-1 programs should confirm that the prescriber is Arizona-licensed or registered under A.R.S. 36-3606 and that the dispensing pharmacy holds an Arizona nonresident permit. [3] [4] [8]

Research use only sellers in Arizona

A.R.S. 32-1931 and rule R4-23-607 prohibit a nonresident from selling or distributing prescription-only drugs into Arizona without a Board nonresident permit, and "research use only" peptides marketed for injection are unapproved new drugs under 21 U.S.C. 331 regardless of labeling. [3] [9]

How to check a compounding pharmacy in Arizona

  1. Search the Arizona State Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Arizona requires before it ships to you. [1] [2] [3] [5]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Arizona. [3] [9]

Common questions in Arizona

How do I check whether a mail-order pharmacy can ship compounded peptides to Arizona?

Search the Arizona State Board of Pharmacy license verification for the pharmacy. Rule R4-23-607 and A.R.S. 32-1931 require a nonresident pharmacy permit before any prescription-only drug is shipped into Arizona. If the pharmacy is not listed, the shipment is unlawful. [1] [3]

Can an Arizona pharmacy compound BPC-157 or other unapproved peptides?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [2] [6] [7]

All peptide legal questions for Arizona

Sources

  1. [1]Arizona State Board of Pharmacy
  2. [2]Arizona Administrative Code R4-23-410, Current good compounding practices
  3. [3]Arizona Administrative Code R4-23-607, Nonresident permits (implementing A.R.S. 32-1931)
  4. [4]Arizona Revised Statutes 36-3606, Interstate telehealth services; registration; requirements
  5. [5]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  6. [6]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  7. [7]FDA: Pharmacy Compounding Advisory CommitteeFDA
  8. [8]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  9. [9]21 U.S.C. 331, Prohibited acts